QWQing Wang

Qing Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qing Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Chunlai Niu

    Department of Respiratory and Critical Care Rehabilitation, Shanghai Second Rehabilitation Hospital, Shanghai, China

    1 shared publication
  • Gang Liu

    Department of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    1 shared publication
  • Hua Shen

    Center for Comprehensive Treatment of Atrial Fibrillation, Department of Cardiothoracic Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China

    1 shared publication
  • Huan Lin

    Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, China

    1 shared publication
  • Ji-Bin Xu

    Center for Comprehensive Treatment of Atrial Fibrillation, Department of Cardiothoracic Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China

    1 shared publication
  • Jian Xiao

    Department of Cardiothoracic Surgery, Changzheng Hospital, Naval Medical University, Shanghai 200003, China

    1 shared publication

Latest Publications

  • Open Access

    Multiomic Mendelian randomization analysis of metabolic gene methylation expression and protein levels in lung adenocarcinoma

    by Qing Wang, Gang Liu, Jun Zhang, Qinguang Zou, Junfeng Geng

    Background Metabolic reprogramming is a hallmark of cancer development, including in lung adenocarcinoma (LUAD). This study aimed to explore the relationships between metabolic gene methylation, expression, and protein levels with LUAD risk using Mendelian randomization, leveraging multi-omic data to identify potential molecular targets for early detection and treatment. Methods The study utilized summary-level data from methylation, expression, and protein quantitative trait loci (QTL) studies. Genetic associations with LUAD risk were sourced from the TRICL Consortium for discovery analysis and validated using data from the FinnGen cohort. Mendelian randomization was conducted to evaluate associations between metabolic gene-related molecular features and LUAD risk, while colocalization analyses were performed to assess whether the identified signals shared causal genetic variants. Results The analysis highlighted significant associations between LUAD risk and specific molecular features of metabolic genes. Among these, CHRNA3 emerged as a key gene of interest, with methylation at two sites significantly associated with increased LUAD risk, supported by strong colocalization evidence. Validation in the FinnGen cohort confirmed the association of one methylation site, strengthening its role in LUAD development. Additionally, expression analyses identified FLOT1 and HYKK as genes with moderate but meaningful associations with LUAD risk, with robust colocalization evidence linking their expression to disease susceptibility. Protective associations were observed for specific protein levels, notably for POGLUT3, which displayed a significant inverse relationship with LUAD risk. These findings collectively identify a set of tier 1 metabolic genes, including CHRNA3, FLOT1, HYKK, and POGLUT3, as central players in the metabolic dysregulation underlying LUAD. Conclusion This multi-omic Mendelian randomization study provides compelling evidence of the role of metabolic genes in LUAD risk. Methylation changes in CHRNA3, altered expression of FLOT1 and HYKK, and protective protein levels of POGLUT3 represent key molecular features associated with disease susceptibility. These findings offer valuable insights into potential molecular targets for early LUAD detection and therapeutic strategies.

  • Open Access

    Impact of pulmonary rehabilitation on exercise capacity, health-related quality of life, and cardiopulmonary function in lung surgery patients: a retrospective propensity score-matched analysis

    by Chunlai Niu, Huan Lin, Zinan Zhang, Qing Wang, Yingjun Wei

    Background: Pulmonary rehabilitation is considered beneficial for patients undergoing lung surgery, yet its specific impacts on exercise capacity, health-related quality of life (HRQL), and cardiopulmonary function require further elucidation. This study aimed to evaluate the effect of PR on these outcomes in patients undergoing lung surgery using a retrospective propensity score-matched analysis.Methods: We retrospectively analyzed 420 patients with non-small cell lung cancer (NSCLC) who underwent lung surgery from January 2022 to May 2024. Among these, 84 patients received PR while 336 did not (control group). Propensity score matching (PSM) at a 1:1 ratio yielded 46 patients in each group. Baseline characteristics, spirometry, cardiopulmonary exercise testing, respiratory muscle strength, HRQL, and muscle measurements were assessed pre-and post-surgery.Results: Before PSM, significant differences existed between groups, with the PR group being older and having different pulmonary function baselines. After PSM, groups were well-balanced. Postoperatively, the PR group showed significant improvements in FEV1/FVC (64.17% vs. 50.87%, p < 0.001), FEV1 (2.31 L/min vs. 1.75 L/min, p < 0.001), and predicted FVC percentage (88.75% vs. 68.30%, p < 0.001). Cardiovascular responses showed a lower CI during exercise in the PR group post-PSM (6.24 L/min/m2 vs. 7.87 L/min/m2, p < 0.001). In terms of exercise capacity, the PR group had higher maximal WR percentage (104.76% vs. 90.00%, p = 0.017) and peak VO2 (1150.70 mL/min vs. 1004.74 mL/min, p = 0.009). PR also resulted in less leg soreness and lower total CAT scores postoperatively. Muscle measurements indicated significantly smaller reductions in ΔHUESMCSA and percentage change in the PR group.Conclusion: Pulmonary rehabilitation significantly enhances exercise capacity, HRQL, and cardiopulmonary function in patients undergoing lung surgery. It also mitigates postoperative muscle loss, underscoring its importance in the postoperative management of lung surgery patients.


  • Open Access

    YKL-40 is highly expressed in the epicardial adipose tissue of patients with atrial fibrillation and associated with atrial fibrosis

    by Qing Wang, Hua Shen, Jie Min, Yang Gao, Kai Liu, Wang Xi, Jie Yang, Liang Yin, Jibin Xu, Jian Xiao, et al.

    YKL-40 (CHI3L1) is a novel biomarker for inflammation, tissue remodeling, and fibrosis, as well as cardiovascular diseases. We investigated the association between YKL-40 expression in epicardial adipose tissue (EAT) and atrial fibrosis in patients with atrial fibrillation (AF). Blood samples, subcutaneous adipose tissue (SAT), paracardial adipose tissue (PAT), EAT, and adjacent atrial myocardium were acquired from patients receiving coronary artery bypass grafts. The patients were divided into the AF group (n = 28) and the sinus rhythm (SR) group (n = 36). We did not detect a significant difference in the serum YKL-40 levels in the SR and AF groups (P = 0.145). Quantitative real-time PCR showed that YKL-40 (CHI3L1) mRNA levels in the EAT were significantly higher than in the SAT or PAT of AF patients, or the EAT of SR patients (All P < 0.001). We found similar results for YKL-40 protein levels by immunohistochemistry. Masson staining showed significantly more fibrosis in AF patients than in SR patients (P < 0.001). Western blotting indicated that AF patients had significantly higher expression of collagen I (P = 0.039). We found a linear relationship between YKL-40 mRNA expression and the collagen volume fraction of the atrial myocardium (y = 3.576x + 26.205, P < 0.001). Multivariate linear regression analysis revealed that body mass index is an independent risk factor for YKL-40 expression in EAT (β = 0.328, P = 0.011). YKL-40, which is highly expressed in the EAT of patients with AF, is affected by body mass index and associated with atrial fibrosis, which may contribute to the development of AF.